Completed Clinical Trials

Inactive Trials

1) A Multicenter, Randomized, Double-blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

2) EISAI E7080- Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine Refractory Unresectable Differentiated Thyroid Cancer Stratified by Histology.

3) A Double-blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-refractory Differentiated Thyroid Cancer.

4) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer

5) A Study of RO5185426 in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

6) A Randomized, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer

7) A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study to Assess the Efficacy and Safety of Vandetanib (Caprelsa) 300 mg in Patients with Differentiated Thyroid Cancer that is Either Locally Advanced or Metastatic

8) RIFTOS MKI (Observational) Radioactive Iodine Refractory Asymptomatic Patients in Differentiated Thyroid cancer: An Observational Study to Assess the Use of MultiKinase Inhibitors

9) An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)